What are CAR T cell therapy, RNA therapy, and other genetic therapies?

CAR T cell therapy is a personalized, cell‑based approach that uses a patient’s own T cells engineered to target cancer cells. Because it is highly specific, it often causes fewer off‑target toxicities such as hair loss or nausea compared with conventional chemotherapy. However, it can trigger a unique set of side effects called cytokine release syndrome (CRS) and neurotoxicity, which may require intensive monitoring and sometimes ICU care. The initial infusion usually takes a few hours, but the overall treatment course—including T‑cell collection, genetic modification, expansion, and infusion—can span 4–6 weeks. In contrast, chemotherapy regimens are typically scheduled over several weeks or months with repeated cycles. How are the risks of RNA therapies, such as antisense oligonucleotides and siRNA, monitored in patients?::RNA therapies are delivered via injections or infusions and can provoke immune reactions, liver enzyme elevations, or injection‑site reactions. Patients are usually monitored with regular blood tests to check liver function (ALT, AST), kidney function (creatinine), and complete blood counts. If a patient develops flu‑like symptoms, a rapid assessment for cytokine release or hypersensitivity is performed. Most centers schedule follow‑up visits within 1–2 weeks after each dose to catch early adverse events and adjust dosing or provide supportive care. Do epigenetic therapies permanently correct genetic disorders, or do patients need ongoing treatment?::Epigenetic therapies target reversible chemical tags on DNA or histones that regulate gene expression. While they can restore normal gene activity in the short term, the underlying DNA sequence remains unchanged. Therefore, many epigenetic drugs require repeated dosing to maintain therapeutic effects. In some cases, a single course may induce durable changes, but most patients need periodic treatment or maintenance dosing to prevent relapse. What criteria determine whether a patient is eligible for CAR T cell therapy or RNA‑based treatments?::Eligibility depends on several factors: the type and stage of disease (e.g., relapsed/refractory B‑cell lymphoma for CAR T), prior treatments, organ function (liver, kidney, heart), performance status, and specific genetic markers. For RNA therapies, the presence of a target mutation or disease mechanism that the RNA can modulate is essential. Patients must also have adequate organ reserve to tolerate potential side effects, and for CAR T, they must be able to undergo leukapheresis to collect T cells. A multidisciplinary review board typically evaluates each case to confirm eligibility.